Loading…
← CockpitCompetitor Analysis › CTKB Cytek Biosciences, Inc.Open in the cockpit ↗

Cytek Biosciences, Inc.CTKBCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 95
Mkt cap
$774M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$7.59M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-45.9 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$5.92
1D+3.9%
1W+2.8%
1M+10.9%
3M+27.0%
6M+57.0%
YTD+17.2%
1Y+11.9%
ATR %5.5%
Beta0.96
52w lowhigh6.5% off high

What Cytek Biosciences does

Employees: 700

Cytek Biosciences at a glance

Size Cytek Biosciences (CTKB) is a United States Health Care company (Medical Specialties) with a market value of $774M, the 2393rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.92 on 18 Nov 2026.

Performance Over six months the shares gained 57.0%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 5.5% over the last twelve months (peer median +12.6%); the operating margin is -21.1% (peer median 12.8%).

Valuation It trades at 2.6× enterprise value to sales against a peer median of 3.4× (8th cheapest of 21).

Capital Return on invested capital runs 45.9 points below its cost of capital (10.6% WACC).

Backlog Backlog (remaining performance obligations) was $49.0M at 30 Sep 2026, up 9% on a year earlier — 0.2 years of trailing revenue. Backlog detail →

Short interest Short interest is 3.1% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026CTKB 149Peer median 84
Six months, rebased to 100: Cytek Biosciences against the median of its 20 peers (local-currency closes).

Cytek Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$208M$201M$200M$193M$164M
Revenue growth—+1%+4%+18%—
Gross profit$114M$104M$111M$109M$102M
EBITDA-$31.9M-$28.4M-$12.6M-$17.1M$4.50M
Net income-$81.2M-$66.5M-$6.02M-$12.1M$2.58M
Free cash flow-$13.5M-$8.77M$21.9M$633,000-$22.0M
Capital expenditure$7.03M$4.19M$3.73M$4.83M$9.87M
Total debt$33.0M$33.0M$27.8M$33.2M$35.9M

Quarterly statements and history in the cockpit →

Cytek Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%MLAB1302VREXBBNX2190SETL300463688108002950300453603108096530AMSMCAP301367688179688805CTKB6-month return →1-month return →
Up and to the right = strong over both horizons. Cytek Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2×4×6×8×MLAB1302VREXBBNX2190SETL300463688108002950300453603108096530INMDAMSMCAP600855301367688179688068688805CTKBRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cytek Biosciences is the large dot.

Cytek Biosciences competitors and peer comparison

How Cytek Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cytek Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureCTKBPeer medianRank in peer set
1-month return+10.9%-8.5%highest of 21
6-month return+57.0%-17.5%3rd highest of 21
Distance from 52-week high-6.5%-41.0%4th highest of 21
Revenue growth (TTM)+5.5%+12.6%8th lowest of 21
Operating margin-21.1%12.8%3rd lowest of 21
EV / Sales2.6×3.4×8th cheapest of 21
ROIC minus cost of capital-45.9 pp-0.3 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%1.2×n/an/a
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%3.6×3.8%+105.8%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%7.7×n/an/a
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%2.3×7.9%-10.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%7.8×27.9%+9.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%1.5×n/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%2.8×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%1.7×20.3%-0.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
InMode INMDUnited States$741M-8%+2%18%0.6×-10.8%+12.4%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%4.5×n/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%1.8×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%5.8×17.1%+24.2%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%

Cytek Biosciences backlog

Cytek Biosciences reported $49.0M of remaining performance obligations at 30 Sep 2026, up 9% from a year earlier and up 4% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 1.03.

Questions

Which companies are Cytek Biosciences's closest peers?
The cockpit's peer set: Mesa Laboratories (MLAB), LifeTech Scientific (1302.HK), Varex Imaging (VREX), Beta Bionics (BBNX), Zylox-Tonbridge Medical Technology (2190.HK), Standard Engineering Technology (SETL.NS), Maccura Biotechnology (300463.SZ), Sino Medical Sciences Technology (688108.SS).
Is Cytek Biosciences expensive compared with its peers?
On ev / sales it trades at 2.6× against a peer median of 3.4×, 8th cheapest of 21 in its peer set.
How has Cytek Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +57.0% against -17.5% for the median peer; over one year +11.9%.
What is Cytek Biosciences's backlog?
Cytek Biosciences's remaining performance obligations (contracted revenue not yet recognised) were $49.0M at 30 Sep 2026, +9% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.